" class="no-js "lang="en-US"> Clinical Trials Archives - Page 35 of 35 - Medtech Alert
Wednesday, July 22, 2026

Sort by:

Date

Top Post

Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial for the Treatment of Rett Syndrome

Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene […]

NEJM Publishes Efficacy of Novavax Vaccine Against B.1.351 Variant

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]

Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]

Cumulus Neuroscience Announces £6 million Funding Round

Cumulus Neuroscience (Cumulus, The Company), formerly known as BrainWaveBank, announces a £6m financing round led […]

ERT and Bioclinica Close Merger, Creating the Global Leader in Clinical Trial Endpoint Technology

ERT, a global leader in clinical endpoint data solutions, today announced the close of its […]

Seed Health Closes $40 Million in Series A Financing

Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, today announced […]

Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

Exscientia, a leading artificial intelligence (AI)-driven pharmatech company, today announced the first AI-designed molecule for […]

Huyabio International Collaboration with Bristol Myers Squibb in Melanoma

HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more